Literature DB >> 9810645

In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: influence of test conditions on minimal inhibitory concentration (MIC) values.

J Boerner1, K Failing, M M Wittenbrink.   

Abstract

A broth microdilution assay was performed to determine the minimal inhibitory concentrations (MICs) of 25 antimicrobial agents for two strains of Borrelia (B.) burgdorferi sensu lato and one strain of B. hermsii. The method comprised BSK II medium lacking gelatin and an incubation period of 72 hours. To investigate the influence of reading mode and density of inoculum on MIC values, microscopical as well as macroscopical MIC reading was performed using standardized final inocula of 10(6) and 10(7) borreliae/ml. Data were processed by two-way analysis of variance. In the microdilution assay, MIC values were significantly influenced either by the inoculum density or reading mode. However, using clearly defined criteria for macroscopical endpoint determination, MICs from macroscopical and microscopical reading were found to be in close agreement. B. burgdorferi sensu lato strains tested were highly susceptible to azithromycin, erythromycin, mezlocillin, piperacillin as well as ceftriaxone, with MICs ranging from < or = 0.016 to 0.125 microgram/ml. B. hermsii was highly susceptible to azithromycin and erythromycin. In comparison to B. hermsii, the beta-lactam antibiotics revealed a significantly higher activity and gentamicin, ofloxacin, and rifampin revealed a significantly lower activity against B. burgdorferi sensu lato strains. To further investigate interactions between BSK II medium, incubation time, and antibiotic efficacy, an agar diffusion bioassay was performed. Out of seven antibiotics tested, the activities of mezlocillin, penicillin G, and piperacillin were significantly influenced by BSK II medium and incubation period and showed a marked decrease of on average 84.0% within 72 hours of incubation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9810645     DOI: 10.1016/s0934-8840(11)80890-x

Source DB:  PubMed          Journal:  Zentralbl Bakteriol        ISSN: 0934-8840


  10 in total

1.  Effects of inoculum size and incubation time on broth microdilution susceptibility testing of lactic acid bacteria.

Authors:  Maria Egervärn; Hans Lindmark; Stefan Roos; Geert Huys; Sven Lindgren
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

2.  In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

Authors:  Klaus-Peter Hunfeld; Eva Ruzic-Sabljic; Douglas E Norris; Peter Kraiczy; Franc Strle
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

Authors:  P Kraiczy; J Weigand; T A Wichelhaus; P Heisig; H Backes; V Schäfer; G Acker; V Brade; K P Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 4.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

5.  In Vitro Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents.

Authors:  Joris Koetsveld; Ronald O P Draga; Alex Wagemakers; Annemijn Manger; Anneke Oei; Caroline E Visser; Joppe W Hovius
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Authors:  Klaus-Peter Hunfeld; Thomas A Wichelhaus; Rebecca Rödel; Georg Acker; Volker Brade; Peter Kraiczy
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

7.  Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi.

Authors:  Eva Sapi; Navroop Kaur; Samuel Anyanwu; David F Luecke; Akshita Datar; Seema Patel; Michael Rossi; Raphael B Stricker
Journal:  Infect Drug Resist       Date:  2011-05-03       Impact factor: 4.003

8.  Identification of novel activity against Borrelia burgdorferi persisters using an FDA approved drug library.

Authors:  Jie Feng; Ting Wang; Wanliang Shi; Shuo Zhang; David Sullivan; Paul G Auwaerter; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2014-07-02       Impact factor: 7.163

9.  Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection.

Authors:  Jie Feng; Wanliang Shi; Shuo Zhang; Ying Zhang
Journal:  Emerg Microbes Infect       Date:  2015-06-03       Impact factor: 7.163

10.  In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.

Authors:  Sanjie Caol; Thomas Divers; Mark Crisman; Yung-Fu Chang
Journal:  BMC Vet Res       Date:  2017-09-29       Impact factor: 2.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.